QyScore

by Qynapse  · Based in France → — AI-powered neuroimaging: Diagnose. Predict. Monitor.
Neurology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Subscription-based
Regulatory Status Disclosed

Overview

Qynapse is a medical technology company dedicated to advancing the accuracy and reliability of Central Nervous System (CNS) disease screening and monitoring. Founded in Paris, France in 2015, as a spin-off from the CATI consortium of neuroimaging research laboratories, Qynapse aims to bring groundbreaking technology to the global fight against CNS disorders.

Its flagship solution, QyScore®, is an AI-powered and proprietary neuroimaging software platform designed to provide physicians, pharma researchers, and payers with an objective layer of precision when making a CNS disease diagnosis. QyScore® produces a wide range of automated neuroimaging biomarkers to assist physicians in making clinical care decisions and monitoring patients over time. The platform is utilized in both clinical routine settings and clinical trial applications, supporting the diagnosis, prognosis, and drug efficacy measurement for various CNS diseases.

QyScore® is FDA-Cleared and CE-Marked, demonstrating superior performance compared to certain other automated state-of-the-art methods and validated against gold-standard manual segmentation. It integrates seamlessly with existing clinical workflows, providing rapid, actionable insights for objective brain scan analysis.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Automated segmentation and volumetric quantification of brain structures and lesions
  • Comparison of patient's brain metrics to a large normative database of healthy subjects
  • Rapidly generated automated patient reports
  • Proprietary and integrated 3D visualization platform
  • Decreases image reading variability and segmentation errors by 89%
  • Compatible with routine clinical workflow and integrates with PACS, AV, AI viewers
  • Supports 1.5T and 3T MRI scanners for T1 MRI processing, and 3T for T2FLAIR MRI
  • Automated measures of neuroinflammation and neurodegeneration
  • Longitudinal charts and 3D rendering for atrophy and disease activity assessment
  • Vendor-neutral and compliant with gold standard brain MRI protocols (ACR, ADNI, OFSEP)

Use Cases

  • Support timely diagnosis of CNS diseases
  • Disease and therapy monitoring
  • Support tailored treatment plans and facilitate therapeutic switching
  • Enhance clinical trial design and improve patient selection
  • Measure drug efficacy and safety in clinical trials
  • Objective brain scan analysis for neurodegenerative disorders

What Physicians Need to Know

Brain MRI Analysis
QyScore provides automated segmentation and volumetric quantification of brain structures (e.g., whole brain, white matter, grey matter by lobe, hippocampus, amygdala, white matter hyperintensities) from 3DT1 and FLAIR MRI images. It quantifies markers for neurodegenerative diseases, compares results to a healthy subject database, and generates automated patient reports rapidly. The software reduces image analysis time and cost by approximately 80% and decreases image reading variability and segmentation errors by 89%. It is FDA-cleared and CE-marked.
Neurodegenerative Disease Screening
QyScore is a core tool for the early diagnosis and clinical monitoring of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. It quantifies key markers such as brain atrophy and white matter hyperintensities, comparing them to a large normative database of healthy subjects to support timely diagnosis and progression monitoring.
Triage Prioritization Speed
The software delivers analysis results and automated patient reports rapidly, often within minutes, contributing to faster clinical decision-making. It aims to reduce overall image analysis time and cost by approximately 80%.
Stroke Detection
Ischemic Stroke detection is listed as 'In Development' for QyScore.
Seizure Detection
Epilepsy is listed as 'In Development' for QyScore.
Physician Tip

QyScore offers objective and precise neuroimaging data, reducing inter- and intra-rater variability in image reading. This supports timely and more accurate diagnosis, facilitates disease and therapy monitoring, and aids in developing tailored treatment plans for patients with CNS diseases like Alzheimer's, MS, and Parkinson's. The rapid generation of automated reports and comparison to a healthy normative database enhances clinical decision confidence and can promote earlier intervention.

QyScore is a cloud-based platform designed for seamless integration into existing clinical workflows, supporting PACS, AV, and AI viewers. It is vendor-neutral for MRI systems, PACS, and viewers, and integrates through DICOM protocols and standards, including DICOM SR, FIHR standards, and DICOM SEG. Deployment options include stand-alone web-based, cloud-based, hybrid solutions, or locally on dedicated hardware.

Details

Category Neurology AI, Radiology & Imaging AI
Pricing Subscription-based
DeploymentCloud-based, compatible with existing workflows through PACS, AV, AI viewers, and a dedicated 3D UI.
Data ExportUnknown
Compliance
BAA AvailableUnknown
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated
GDPR Yes AI-estimated
Integrations
EHR Not specified
Specialties Neurology, Radiology

What the Web Says

QyScore, developed by Qynapse, is an FDA-cleared and CE-marked neuroimaging analysis software designed to quantify brain MRI markers for neurodegenerative diseases like Alzheimer's, Parkinson's, and multiple sclerosis. It aims to provide rapid, precise, and objective MRI brain imaging analysis, reducing variability and aiding in timely diagnosis and monitoring of disease progression. The software generates automated patient reports and offers 3D visualization of results, comparing them to a normative database of healthy subjects.

Overall: Positive

Strengths

  • Automated and rapid quantification of neurodegenerative and neuroinflammatory markers.
  • Reduces inter-rater and intra-rater variability in image reading and segmentation errors.
  • Aids in early and timely diagnosis of dementias and other CNS diseases.
  • Supports disease and therapy monitoring, and tailored treatment plans.
  • Provides objective measures for clinical trials, enhancing trial design and patient selection.
  • Cloud-based, easy to use, and scalable.

Limitations

  • Not intended for use in clinical scenarios requiring evaluation of the number of white matter hyperintensities in the U.S. (FDA indication).
  • While automated, the final clinical decision still relies on expert physician review.
  • Limited public reviews from independent sources like Reddit, G2, or Capterra make it difficult to assess broader user sentiment beyond official statements and medical publications.

Based on reviews from: NeurologyLive, PMC, Qynapse (qynapse.com), MedicalExpo, AuntMinnie, PR Newswire UK

Last updated: 2026-10-21

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate QyScore

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

PR Newswire
Qynapse Releases Data Highlighting the Accuracy of QyScore® and Predictive performance of QyPredict® for Disease Progression in preclinical Alzheimer's Disease
Qynapse presented new data at the Alzheimer's Association International Conference (AAIC) for QyScore and QyPredict, demonstrating QyScore's higher segmentation accuracy and reliability over other established products, and QyPredict's ability to identify patients with preclinical AD and MCI likely to experience cognitive decline.
2025-07
Multiple Sclerosis News Today
QyScore Brain Imaging Software Earns FDA 510(k) Clearance
QyScore, an imaging software by Qynapse that automatically analyzes MRI markers of brain disease, received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The software standardizes image analysis, reduces variability, and provides reliable results in minutes, aiding in the early diagnosis of neurodegenerative diseases.
2020-02
NeurologyLive
FDA Clears QyScore Imaging Software for CNS Diseases
Qynapse received FDA clearance for its QyScore imaging software, designed for central nervous system diseases. The software provides automated quantification of MRI markers to support early diagnosis and clinical monitoring of neurodegenerative disorders.
2020-02
AuntMinnie
FDA clears Qynapse's brain MRI analysis software
Qynapse announced it received 510(k) clearance from the FDA for its QyScore brain MRI analysis software. QyScore quantifies disease markers like brain atrophy and white-matter lesions on MR images, generating reports within minutes to support differential diagnosis and monitor drug efficacy.
2020-02
Qynapse (Press Release)
Qynapse receives FDA clearance for QyScore®, a novel imaging software for central nervous system diseases
Qynapse announced FDA 510(k) clearance for its QyScore® software, which provides automated quantification of MRI markers for early diagnosis and clinical monitoring of neurodegenerative disorders like Alzheimer's, Parkinson's, and multiple sclerosis.
2020-02
Radiology Business
Paris tech company scores FDA clearance for brain MRI assistant
Qynapse received FDA clearance for its QyScore software, an AI-powered tool that assists radiologists in diagnosing brain diseases by pinpointing and quantifying brain atrophy and other MRI markers. The program generates patient reports quickly and compares results to a database of healthy patients.
2020-02
PubMed (European Radiology)
Validation of an automatic tool for the rapid measurement of brain atrophy and white matter hyperintensity: QyScore®
This peer-reviewed article validates QyScore®'s performance for automatic volumetry of grey and white matter, hippocampus, amygdala, and white matter hyperintensity, comparing its results with the consensus of expert neuroradiologists.
2022-01
Qynapse (Press Release)
Qynapse releases new data demonstrating the value of QyScore® for the clinical assessment of Multiple Sclerosis (MS)
Qynapse released new data highlighting the value of QyScore® for the clinical assessment of Multiple Sclerosis, demonstrating how its normative database can improve individual assessment of brain neurodegeneration in RRMS patients.
2020-09

Videos

Product demos, reviews, and walkthroughs for QyScore.

View all on YouTube

Frequently Asked Questions

QyScore is an AI-powered neuroimaging software platform that automatically analyzes brain MRI markers for neurodegenerative diseases like Alzheimer's, Parkinson's, and multiple sclerosis. It quantifies brain structures, such as whole brain, white matter, grey matter by lobe, and white matter abnormalities, and compares them to a database of healthy subjects. This aims to provide objective measures to support timely diagnosis, monitor disease progression, and aid in tailoring treatment plans.
Yes, QyScore is FDA-cleared in the U.S. and CE-marked in Europe, indicating its compliance as a medical device. Qynapse, the company behind QyScore, states that it is HIPAA and GDPR compliant, ensuring data privacy and security.
While QyScore offers significant advantages, it's important to note that the current version of its algorithm for grey matter segmentation is not optimized for excluding white matter lesions, requiring review of results before clinical use. Additionally, while it provides valuable data, the final clinical decision remains with the physician.
QyScore has demonstrated higher segmentation accuracy and greater reliability compared to other established automated methods like FreeSurfer, FSL, and ANTs. It aims to reduce image reading variability and segmentation errors often associated with manual or semi-automatic methods, providing consistent and fast analysis.
QyScore is designed to integrate seamlessly with existing clinical workflows, including PACS, AV, and AI viewers, and can generate automated patient reports. While specific pricing models are not publicly detailed, interested physicians can request a demo from Qynapse to learn more about its integration and potential costs.

Related Tools

Parkiwatch
Koios Care
Neurology AI
Parkiwatch by Koios Care is a Class IIa Software as a Medical Device (EU MDR 2017/745) for continuous, passive detection and quantitative assessment of kinematic patterns representative of tremor, bradykinesia, and dyskinesia in adults with Parkinson's Disease.
Paid
CortiCare (Virtual EEG Department)
CortiCare
Neurology AI
CortiCare offers 24/7 remote EEG monitoring and interpretation services, functioning as a virtual EEG department to assist hospitals and neurology practices in identifying seizures and other neurological conditions.
NeuroAstra
Avinya NeuroTech
Clinical Decision Support & Reference
NeuroAstra is an AI-enabled EEG analysis and reporting software that provides a multimodal clinical EEG web platform with Co-Pilot AI to help neuro care teams detect abnormal trends faster and standardize reporting.
Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
CoLumbo C-Spine
Smart Soft Healthcare AD
Clinical Decision Support & Reference
CoLumbo C-Spine is an AI-powered software that processes and analyzes cervical spine MRI exams, assisting clinicians in diagnosis and assessment.
MeRT System
Wave Neuroscience
Mental & Behavioral Health AI
MeRT (Magnetic e-Resonance Therapy) is an advanced, personalized form of TMS that uses your own brainwave data to guide treatment. It's a non-invasive, drug-free option designed to help the brain communicate more efficiently so symptoms of conditions like depression, anxiety, PTSD, TBI, autism, and more can improve.
Paid

See all Neurology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-20 | First Added: 2026-04-20
AI Tool Finder
AI-powered search. Results may not be comprehensive.